Guobang Pharma (SHSE:605507) Marketable Securities: ¥1,075 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605507 Guobang Pharma Ltd SHSE:605507
86 GF Score
Price ¥16.04
GF Value ¥15.66
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Guobang Pharma Marketable Securities?

Guobang Pharma SHSE:605507 +2.23% 86 Marketable Securities is ¥1,075 Mil as of Jun. 2026. GuruFocus rates SHSE:605507 with a GF Score™ of 86/100 and a GF Value™ of ¥15.66 (Fairly Valued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Guobang Pharma's Marketable Securities for the quarter that ended in Jun. 2026 was ¥1,075 Mil.

Guobang Pharma's annual Marketable Securities increased from Dec. 2023 (¥466 Mil) to Dec. 2024 (¥618 Mil) and increased from Dec. 2024 (¥618 Mil) to Dec. 2025 (¥1,243 Mil).

Guobang Pharma  (SHSE:605507) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Guobang Pharma Marketable Securities Related Terms

Guobang Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Guobang Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guobang Pharma Marketable Securities Chart

Guobang Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 1,258.26 824.56 465.99 617.66 1,242.96

Guobang Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 693.89 896.34 1,242.96 1,253.63 1,075.02
SHSE:605507
86GF Score
Guobang Pharma Ltd SHSE:605507
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guobang Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ¥1,075 Mil mean?
Guobang Pharma (SHSE:605507) has a Marketable Securities of ¥1,075 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Guobang Pharma and its competitors.
Is Guobang Pharma's Marketable Securities too high?
Guobang Pharma's current Marketable Securities is ¥1,075 Mil. Overall, Guobang Pharma has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's Marketable Securities compare to ZTS?
Guobang Pharma's Marketable Securities of ¥1,075 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Guobang Pharma and its competitors. Guobang Pharma's current Marketable Securities is ¥1,075 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.66, compared to a current price of ¥16.04 — trading 2.4% above its estimated fair value. The current Marketable Securities is ¥1,075 Mil. Guobang Pharma's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current Marketable Securities is ¥1,075 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guobang Pharma (SHSE:605507) Overvalued in 2026?

Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued. The current stock price of ¥16.04 is trading 2.4% above its estimated GF Value™ of ¥15.66. GuruFocus considers Guobang Pharma to be Fairly Valued.

Key valuation signals for SHSE:605507:

  • Marketable Securities: ¥1,075 Mil
  • GF Value™: ¥15.66 vs. price of ¥16.04 (2.4% above fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guobang Pharma Business Description

Address No. 60, Xingmei Avenue, Provincial High-tech Industrial Park, Zhejiang Province, Xinchang, CHN, 312500
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
86GF Score

Get the complete analysis for SHSE:605507

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.04
Price
¥15.66
GF Value